Oric PharmaceuticalsORIC
Recorded

Oric Pharmaceuticals 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration24 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Paul JengAnalyst

I am very pleased to be joined by Dominic Piscitelli, CFO, and Matthew Panuwat, Chief Business Officer.

Dominic PiscitelliCFO

Welcome. Thanks for having us, Paul.

Paul JengAnalyst

Good to see you. All right, so maybe just to kick things off for those that might be newer to the story, could you provide a quick overview of ORIC and your two late-stage programs that are in the clinic right now?

Dominic PiscitelliCFO

Sure. ORIC Pharmaceuticals is a clinical-stage oncology company. Our name really encapsulates our mission, which is to overcome resistance in cancer. As Paul said, we have two late-stage clinical programs. The first one, rinzimetostat, this is an allosteric PRC2 inhibitor we are studying in prostate cancer in combination with AR inhibitors, and that study, we actually started our first phase III study earlier this year, which is known as Himalayas-1. The second program is enozertinib. This is an EGFR TKI. We are targeting two distinct patient populations, both EGFR atypicals as well as EGFR exon 20. We had some data in the atypical patient population at ESMO earlier this year, which I am sure we will talk about, and we expect to start our first phase III study for that in the first half of next year.

Paul JengAnalyst

All right, fantastic. Maybe beginning with rinzimetostat, I think it is fair to say all eyes on the space are on the MEVPRO-1 upcoming readout for Pfizer's mevrometostat, which will be a possibly defining readout for the class. Maybe just to start with, can you talk about how rinzi and mevro differ fundamentally in terms of target pharmacology and how that might translate to a potentially different clinical profile?

Matt PanuwatChief Business Officer

Sure. Yeah, a couple things on the nuances there. I think both are PRC2 inhibitors, so we are actually going after the same target. We are doing that in a little bit of a different way, so we are actually binding a separate binding pocket on the PRC2. As Dominic said, we call it an allosteric PRC2 inhibitor, so we are binding what is called the EED subunit, whereas other molecules before us, the earlier generation molecules, inhibit EZH2, which is the catalytic subunit. What we have seen from, based on a number of preclinical research, it seems to be very similar pharmacology. You are basically having the same impact on genetic signaling, very similar potency. I think us and mevrometostat, very high potency, much higher than earlier generation molecules, very strong in vivo data.

Matt PanuwatChief Business Officer

What we are doing, we are actually inhibiting the target differently, and the main advantages we have seen preclinically is that you can actually have much better molecules binding to that pocket, and I think what I mean by that is just the drug properties are much improved in being an EED inhibitor in rinzimetostat. I think everything that you come to select for a molecule, improved solubility, the potency, bioavailability, all of those drug properties that you really want from a preclinical standpoint, that is really where our drug stands out. What we have seen in the clinic, I think, for example, is our recommended phase III dose is 400 milligrams once daily. We have seen really nice PK profile, a 24-hour half-life, so it is an easily once-daily therapy. What we have seen from the earlier generation molecules, including Pfizer's mevrometostat, is a very short half-life.

Matt PanuwatChief Business Officer

I think we estimate mevrometostat's probably in the three or four-hour half-life. They have to dose with very significant amount of drug. The randomized phase II dose was 1,250 BID in combination with enzalutamide. High doses, very frequent dosing, so they're able to kind of have target coverage. I think with that comes a lot of safety advantages from what we've seen from our earlier data. The data we've presented so far from an efficacy standpoint seems to be generally consistent, is what we have shown, but where the differences really differ is on the safety profile.

Matt PanuwatChief Business Officer

I think a lot of the data that other people have reported is a lot of the safety adverse events are really Cmax-driven, so you tend to have those issues when you have a short half-life molecule that is dosing frequently and high doses, whereas we have a much more sustained profile. So at least so far, it seems like we have a much better, more tolerated regimen.

Matt PanuwatChief Business Officer

Yeah. I think we feel comfortable with that so far.

Matt PanuwatChief Business Officer

We hope either one, that could play out to patients staying on drug for a longer period of time. Obviously, safety is always helpful. Then two, what we've seen commercially in prostate cancer is that there are a nice analog with AR inhibitors. There's three approved, enzalutamide, apalutamide, and darolutamide. Darolutamide is our combination partner of choice, but interestingly, when you look at that as a commercial analog, that was the third AR inhibitor approved, indistinguishable on efficacy, very different safety profile. That is now the number one selling ARPI in its approved indications in the U.S. I think that's a good example of safety can kind of matter pretty significantly in prostate cancer, but again, our data will continue to mature.

Dominic PiscitelliCFO

Yeah, maybe just to add to that, Paul, as Matt said, that we're combining with darolutamide, Pfizer's combining with enzalutamide. Both enzalutamide and apalutamide are CYP inducers, so you have that DDI impact, which does require you to increase the dose in order to maintain the exposure. That could also be driving why we have a better safety profile is, so what we've seen so far, and less inter-patient variability.

Paul JengAnalyst

Sure. Makes a lot of sense. Sticking with the read-through from MEVPRO-1, Pfizer recently honed the timing to February of next year. Any thoughts first on that timing, and how do you think about the range of scenarios around study success or failure that you are contemplating ahead of the readout?

Dominic PiscitelliCFO

Yeah. There has been a lot of movements, I guess, with the timing of that study. I think the original primary completion date that they had on ClinicalTrials.gov was mid-2026. On their Q2 earnings call, they did say that that data would be in Q4, and as you pointed out, on their Q3 earnings call, they kind of shifted that to February of next year. The first thing is, if you take a step back, there has been a lot of data of seeing PRC2 inhibitors, with combination with AR inhibitors, showing some pretty interesting data. Pfizer had about four or five datasets. We saw another competitor, Agrimetastat, that showed some pretty interesting data as well. We saw our data as well. From our standpoint, there is a lot of good biological rationale.

Dominic PiscitelliCFO

We have got a lot of good clinical data supporting the rationale of combining a PRC2 inhibitor with an AR inhibitor. When we think about scenarios, historically, we kind of broke it down into four buckets. There was kind of the big miss, the small miss, the small hit, and the big win, let us call it. I think based on the timing and based on event-based modeling, we have done as well as a number of analysts, I think most people would say that the kind of the big miss is probably off the table. Obviously, if we think about what we would want, we would want them to hit, we think it is further validation for the mechanism. Is there a scenario where there is a near miss by Pfizer? It is possible. Obviously, we would have to see what that rationale was.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day